LEXINGTON, Mass., Aug. 28, 2018 /PRNewswire/ -- Pulmatrix,
Inc. (NASDAQ: PULM) will present at the Rodman & Renshaw 20th
Annual Global Investment Conference on Wednesday, September 5, 2018 at 10:00 AM EDT in the Lotte New York Palace Hotel
in New York City. As part of the
presentation, Robert Clarke, Ph.D.,
chief executive officer of Pulmatrix, will provide an update on the
Company's business and its pipeline of inhaled therapeutics.
Among the highlights of the presentation will be positive data
from a phase 1/1b clinical study of
Pulmatrix's Pulmazole, an inhaled an
inhaled iSPERSETM formulation of the
anti-fungal drug itraconazole for the treatment of allergic
bronchopulmonary aspergillosis in patients with asthma.
About Pulmatrix
Pulmatrix is a clinical stage
biopharmaceutical company developing innovative inhaled therapies
to address serious pulmonary disease using its patented iSPERSE™
technology. The Company's proprietary product pipeline is focused
on advancing treatments for serious lung diseases, including
Pulmazole, inhaled anti-fungal itraconazole for patients with ABPA,
and PUR1800, a narrow spectrum kinase inhibitor for patients with
obstructive lung diseases including asthma and chronic obstructive
pulmonary disease ("COPD"). In addition, Pulmatrix has partnered
with Vectura Group plc to develop Pulmatrix's long-acting
muscarinic antagonist drug candidate, PUR0200, for COPD for the
U.S. market. Pulmatrix's product candidates are based on iSPERSE™,
its proprietary engineered dry powder delivery platform, which
seeks to improve therapeutic delivery to the lungs by maximizing
local concentrations and reducing systemic side effects to improve
patient outcomes.
FORWARD-LOOKING STATEMENTS
Certain statements in this
press release that are forward-looking and not statements of
historical fact are forward-looking statements within the meaning
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The Company cautions that such statements
involve risks and uncertainties that may materially affect the
Company's results of operations. Such forward-looking statements
are based on the beliefs of management as well as assumptions made
by and information currently available to management. Actual
results could differ materially from those contemplated by the
forward-looking statements as a result of certain factors,
including but not limited to the ability to establish that
potential products are efficacious or safe in preclinical or
clinical trials; the ability to establish or maintain
collaborations on the development of therapeutic candidates; the
ability to obtain appropriate or necessary governmental approvals
to market potential products; the ability to obtain future funding
for developmental products and working capital and to obtain such
funding on commercially reasonable terms; the Company's ability to
manufacture product candidates on a commercial scale or in
collaborations with third parties; changes in the size and nature
of competitors; the ability to retain key executives and
scientists; and the ability to secure and enforce legal rights
related to the Company's products, including patent protection. A
discussion of these and other factors, including risks and
uncertainties with respect to the Company, is set forth in the
Company's filings with the Securities and Exchange Commission,
including its annual report on Form 10-K filed by the Company with
the Securities and Exchange Commission on March 13, 2018, as may be supplemented or amended
by the Company's Quarterly Reports on Form 10-Q. The Company
disclaims any intention or obligation to revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
Investor
Contact
|
|
Robert Clarke,
CEO
|
William Duke,
CFO
|
(781)
357-2333
|
(781)
357-2333
|
rclarke@pulmatrix.com
|
wduke@pulmatrix.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/pulmatrix-to-present-at-the-20th-annual-rodman--renshaw-global-investment-conference-on-september-5-2018-300702794.html
SOURCE Pulmatrix, Inc.